Healthtech & Wellness VC Funds

Maverick Ventures is the venture capital arm of Maverick Capital, a multi-billion dollar hedge fund platform managing approximately $12.5 billion in AUM. Founded in 2015 in San Francisco, Maverick Ventures operates as an evergreen fund structurally integrated with the hedge fund platform, giving portfolio companies access to hedge-fund-grade analysts and public company networks that conventional VC firms cannot match. By March 2025, the firm had raised over $240 million for its fourth vintage — led by Kindred Capital with Y Combinator, Rebel Fund, and Concept Ventures joining — bringing total capital raised to $855 million and AUM to $1.4 billion. Managing Partner David Singer, a repeat founding CEO of three public companies, leads a deliberate five-person investing team that backs only a select number of companies per year to enable deep engagement with each founder. The firm focuses on healthcare innovation and enterprise AI, investing from Seed through Series C and beyond with check sizes typically between $3 million and $50 million. Maverick leads rounds. Across 83 total investments, the portfolio has produced 10 unicorns, 12 IPOs, and 37 acquisitions. Notable exits include Hims and Hers (seed investor through its 2021 IPO), BioCatch (sold to Permira for $1.3 billion in 2024), Coupang, One Medical, and Tata 1mg. Recent investments include Oula Health ($28 million Series B co-led, December 2024) and Garner (healthcare technology, February 2026). Approximately 30 percent of fund capital comes from Maverick partners and employees — the largest single LP — a structural feature that aligns the partnership's own capital with founder outcomes. Maverick's integration with a mature public markets platform allows it to support companies from first institutional check through post-IPO holding, providing continuity of partnership that few venture platforms can offer.

Maverick Ventures (Israel) is a Tel Aviv-based venture capital firm founded in 2013 by Yaron Carni, who previously founded the Tel Aviv Angel Group and sold the first Israeli company acquired by Google. Managing Partner Michel Abadi leads a team of 11 including three partners. The firm operates as a multi-stage platform across six funds, including Maverick Ventures Israel III, collaborating across private and public strategies to support companies from inception through IPO. A notable structural feature: 30 percent of the firm's capital is committed by Maverick partners and employees, representing the largest single LP position in the fund. Maverick invests $1 million to $3 million at Seed through Series B stages and leads rounds. The firm is sector-agnostic except for explicit exclusions covering crypto and blockchain, medical devices, chips and semiconductors, and ad tech. Since early 2023 the investment focus has centered on AI-adjacent and infrastructure-supporting companies. Across 83 total investments, the portfolio has produced 2 unicorns — Taboola and Redis — along with 2 IPOs and 16 acquisitions across 21 exits. Recent investments include Hirundo ($8 million seed for AI optimization and machine unlearning, led by Maverick, June 2025), Commure (healthcare enterprise systems, June 2025), and Wild Moose (Seed, October 2025). Other notable portfolio companies include Vendi AI, Artemis Health, and Aptible (exit November 2025). The firm's name derives from the Hebrew word meaning 'to shine,' reflecting an investment culture oriented toward conviction and differentiation. Maverick's willingness to lead from seed through late stage, combined with the large GP and team co-investment, aligns the partnership's financial interests tightly with those of portfolio founders.

Maveron, a consumer-only venture capital firm, was founded in 1998 by Dan Levitan and Howard Schultz, the visionary behind Starbucks. The firm focuses on early-stage investments in transformative consumer brands. With a keen understanding of consumer behavior and market trends, Maveron has built a diverse portfolio that includes notable companies like Allbirds, Everlane, and Zulily. Maveron operates with a mission to back entrepreneurs who aim to change how people live, work, learn, play, eat, and stay well. Their investments span various consumer sectors such as health and wellness, e-commerce, and food innovation. Some of their prominent exits include eBay, Trupanion, and Potbelly Sandwich Works. The firm recently raised $225 million for its eighth fund, continuing its legacy of identifying and supporting early-stage consumer startups. Maveron's team, led by experienced partners like Dan Levitan and Jason Stoffer, brings deep industry knowledge and a commitment to fostering long-term partnerships with entrepreneurs.

Max Ventures, founded in 2013 by Ryan Darnell and Sophie Stenbeck, is a dynamic seed-stage venture capital firm based in New York. Notable for its early investments in companies like Boxed, ZoomCar, Button, and Drone Racing League, Max Ventures focuses on consumer tech and health-tech startups. The fund targets North American markets and emphasizes investing in founders with unique consumer insights and relentless drive. Max Ventures typically makes initial investments ranging from $750K to $1M, often leading the rounds. Their strategy involves a hands-on approach, leveraging their extensive network to support portfolio companies in achieving significant growth. The fund is particularly interested in startups within the fashion/beauty, food and beverage, internet and web services, real estate, and software industries. The team, including key figures like Managing Partner Matthew Weinberg, prides itself on its ability to identify and nurture innovative talent. Startups looking to approach Max Ventures should focus on demonstrating strong consumer insight and a clear execution plan. Recently, the firm has been active with investments like UnityAI in healthcare technology, showcasing their ongoing commitment to pioneering advancements in tech.

Max Ventures and Industries Limited (MVIL) is a publicly listed Indian company on the NSE and BSE exchanges, part of the $3 billion Max Group conglomerate founded by Analjit Singh in 1985 and headquartered in New Delhi. MVIL serves as the holding company for Max Estates (real estate development), Max Speciality Films (packaging and labeling films), MAX Learning, and MAX I., its investment subsidiary. Under CEO and Managing Director Sahil Vachani, the company generated revenue of approximately 1,200 crore rupees in FY2024. The investment arm has made approximately 22 venture investments across the United States, India, Sweden, and other markets, spanning enterprise applications, retail, consumer, healthcare, and digital commerce. Check sizes have typically been in the $1 million to $3 million range at Seed through Series B stages. The portfolio has achieved significant outcomes including one unicorn — K Health, an AI-powered primary care platform that achieved unicorn status in 2021, with MVIL backing the company since seed stage — and two IPOs: Nykaa (listed on the BSE and NSE in November 2021 at a $7.14 billion market capitalization) and Avnet (NYSE). Five portfolio companies have been acquired. MVIL's investment approach reflects its position as the venture and innovation arm of a diversified conglomerate, with a board that includes founder Analjit Singh, Arvind Aggarwal, Bishwajit Das, Tara Singh Vachani, and Sahil Vachani. The fund identifies sunrise sectors where MVIL's industrial and consumer network can provide portfolio companies with market access and operational credibility beyond what a purely financial investor could offer.

Maxfield Capital is a venture capital firm specializing in early-stage investments, focusing on IT and internet sectors. Established in 2013 by Alexander Turkot, the firm has a global presence with offices in New York, Tel Aviv, and Moscow. Maxfield Capital aims to bridge the gap between high-quality engineering and commercial execution, helping startups scale globally. The firm's investment focus includes sectors such as e-health, digital lending, data protection, mobility, e-education, marketplaces, and cloud computing. Maxfield Capital typically invests in companies that are beyond the seed stage, preferring those with more advanced development​. Alexander Turkot, the founder and managing partner, brings extensive experience from his background in IT, engineering, and project management, including significant roles at IBM and the Skolkovo project. Other key partners include Oleg Koujikov and Alexander Lazarev, who manage operations across various regions.

Maya Capital, founded in 2018 by Lara Lemann and Monica Saggioro, is a venture capital firm based in São Paulo, Brazil. The firm focuses on early-stage investments in Latin American startups, aiming to lead the first institutional funding rounds and provide hands-on support to its portfolio companies. Their approach includes assisting with hiring, go-to-market strategies, and fundraising efforts. Maya Capital's portfolio includes notable investments such as NotCo, a food tech company specializing in plant-based products, and Merama, an e-commerce platform aggregator. These investments have elevated both companies to unicorn status, showcasing Maya Capital's ability to identify and nurture high-potential startups. With the recent close of their second fund at $100 million, Maya Capital plans to invest in 25 to 30 new companies, with a significant portion reserved for follow-on funding. The firm aims to support the best founders in Latin America and expand their reach among Spanish-speaking entrepreneurs across the region. Their investment strategy balances a strong presence in Brazil with significant investments throughout other Latin American countries, such as Mexico, Colombia, and Chile. Maya Capital emphasizes long-term partnerships and being an integral part of their portfolio companies' journeys from early stages to successful scaling. This commitment is reflected in their proactive support and the extensive network they leverage to benefit the startups they invest in.

Mayfield is a renowned venture capital firm founded in 1969, with a focus on early-stage investments. The firm is based in Menlo Park, California, and has a strong presence in the U.S. and India. Mayfield has made significant contributions to the tech industry, backing over 852 companies, including notable names like Lyft, Couchbase, and Poshmark. Mayfield’s portfolio showcases a diverse range of sectors, emphasizing artificial intelligence, enterprise software, consumer tech, semiconductors, and human and planetary health. Some of their standout investments include Unstoppable Domains, Amagi, and BigPanda, which have grown into unicorns under their guidance. The firm has also successfully shepherded companies to IPO, such as Lyft and Couchbase, and facilitated numerous high-profile acquisitions. The firm operates with a "people-first" investment philosophy, aiming to partner with visionary entrepreneurs from inception through growth stages. They typically invest in Seed, Series A, and Series B rounds, providing not only capital but also strategic support and mentorship. Mayfield's investment team includes seasoned partners like Navin Chaddha and Ursheet Parikh, who bring extensive industry experience and a track record of successful exits. Mayfield's investment strategy involves close collaboration with founders, focusing on building enduring companies that can achieve market leadership. Founders looking to connect with Mayfield should highlight their innovative solutions and potential for significant impact, aligning with the firm’s mission to back transformative technologies.

MariaMazarine Ventures is a Chicago-based venture capital firm dedicated to addressing the global water crisis through technology. Founded in 2018, Mazarine exclusively invests in early-stage startups that are developing innovative solutions for managing water and wastewater-related risks across various industries. These sectors include agriculture, aquaculture, climate tech, and industrial applications, among others. The firm operates multiple funds, each with a unique focus. Fund II, for instance, targets companies with proven commercial traction—often nearing $1 million in annual sales—and intellectual property rooted in fields like chemistry, data science, and materials science. Mazarine typically leads seed and early Series A rounds, cutting checks between $25,000 and $500,000, and often continues to support its portfolio companies through follow-on investments. Mazarine’s investment strategy is centered on mitigating critical risks—such as public health, environmental protection, and business continuity—posed by water scarcity and quality issues. The firm’s approach extends beyond financial backing; it leverages a network of experienced operators and co-investors to provide strategic support, helping startups scale and achieve meaningful impact. The leadership team, including co-founders John Robinson, Pete Nassos, and Anders Hallsby, brings decades of experience in commercializing water and wastewater technologies. Mazarine’s rigorous focus on ESG (Environmental, Social, and Governance) metrics underscores its commitment to not only financial returns but also substantial environmental and social impact​. wll do on Thu

in 2001, MBVP primarily focuses on medical device startups, particularly those addressing musculoskeletal diseases. Notable investments include startups acquired by industry giants like Johnson & Johnson, Medtronic, Smith + Nephew, Zimmer Biomet, and Wright Medical (now part of Stryker). MBVP's strategy emphasizes providing not just capital but also strategic direction, leveraging their deep industry connections and expertise. They typically invest at all stages of development, ensuring that startups have the support they need from inception through to exit. The firm is known for its active role in the Musculoskeletal New Ventures Conference, a testament to its leadership in the sector. The team is led by co-founder Gary Stevenson, whose background includes significant roles in healthcare investment banking, equity research, and general management at Abbott Laboratories. Gary's comprehensive experience and his educational background, including an MBA from Northwestern University's Kellogg School of Management, underscore the firm's robust leadership. MBVP prefers to be approached by startups with a clear, compelling value proposition in the life sciences sector. They are known for writing substantial checks and often lead investment rounds. Their involvement in over 50 startups highlights their active investment approach and commitment to advancing medical innovations​.

MBX Capital, established in 2015, is a venture capital firm headquartered in Claymont, Delaware. The firm specializes in early-stage investments within the healthcare and life sciences sectors, focusing on pre-seed, seed, and Series A rounds. MBX Capital has a robust portfolio that includes companies like Luna, Concert Health, Koneksa Health, Atlas Labs, and Buoy Health​. Notable recent investments by MBX Capital include Vivodyne, which raised $38 million in November 2023, and Macro Trials, which secured $6 million in June 2023. These investments underline the firm's commitment to advancing biotechnology and clinical trials​ (PitchBook)​. Additionally, MBX Capital led a $10.7 million Series A financing for Contraline, supporting the development of innovative medical technologies​​. The firm's co-founders, Gurdane Bhutani and Zeshan Muhammedi, lead a team that provides hands-on support to portfolio companies, leveraging their expertise and extensive network to drive growth and innovation​​. MBX Capital's strategic approach and active involvement make it a key player in the venture capital landscape for healthcare and life sciences startups.

McNamara Family Ventures (MFV) is a Brentwood, Tennessee-based family investment office providing venture and growth capital exclusively to companies in the healthcare industry. The firm was founded by Kevin McNamara, a veteran healthcare finance executive who served as CFO of HealthSpring Inc. from 2005 to 2009 and oversaw the company's NYSE listing in February 2006. HealthSpring was subsequently acquired by Cigna Corporation for $3.8 billion in 2012, establishing McNamara's track record as an operator with direct experience in building and exiting a scaled healthcare services company. MFV targets Series A and Series B stage investments with check sizes typically in the $1 million to $10 million range. The firm invests across the broader healthcare sector, drawing on McNamara's operating experience spanning healthcare, business services, retail, and manufacturing, as well as significant private equity experience. He holds a BS from Virginia Commonwealth University, an MBA from the University of Richmond, and is a CPA. He currently serves on the boards of Tyson Foods (NYSE), Luminex Corporation, and Leon Medical Centers. The only publicly documented investment is DigiScript (recapitalization, September 2006). MFV positions itself as an active capital provider rather than a passive financial investor, helping portfolio management teams with business plan development, strategic planning, tactical execution, mergers and acquisitions, strategic partnerships, and key talent recruitment. The firm operates quietly within the Nashville healthcare ecosystem, prioritizing a focused mandate over portfolio breadth.

MD ONE Ventures is a London-based venture capital firm founded in 2021, operating as Europe's dedicated national security venture capital fund. The firm invests in product-focused deep tech businesses with strong commercial foundations that have the potential to advance European and allied nations' national security capabilities. Managing approximately $200 million in AUM, the team of eight includes two partners and two venture partners who combine comprehensive VC experience across more than 12 subsectors and 150 historic transactions with operational backgrounds from Tier One Special Forces and Intelligence Communities. MD ONE leads rounds with check sizes of $10 million to $50 million, covering a wide spectrum within the defense and security universe: cyber, AI, machine learning, autonomy, robotics, drones, space, life sciences, SaaS, medtech, and communications — both software and hardware companies with national security, enterprise, and defense backgrounds. The portfolio of 21 investments includes a major pending public listing: XTEND, an AI-driven autonomous defense robotics company, announced a $1.5 billion Nasdaq listing through a merger with JFB Construction Holdings expected in mid-2026 under the ticker XTND. Other portfolio companies include Greenjets (electric propulsion for drones and aircraft, $7 million pre-Series A, December 2025), Airfinity (disease forecasting platform), Milvus Advanced (metals and minerals for defense), Pimloc, and Labrys. The firm made three investments in 2024 and four in the first half of 2025. MD ONE's cross-disciplinary team — combining VC investment expertise with firsthand special operations experience — allows it to evaluate dual-use technologies and defense applications with operational credibility that financial-only investors lack. The firm's mission is to ensure that Europe and its allies maintain technological superiority through commercially robust companies at the frontier of defense innovation.

MD Start is a unique medtech incubator and fund based in Paris, dedicated to transforming early-stage medical device ideas into commercially viable companies. Founded in 2010, it partners with leading institutions like Medtronic, Bpifrance, and Sofinnova Partners to support innovative concepts that are too early for traditional venture investment. MD Start’s approach is hands-on, focusing on developing, managing, and de-risking projects to attract later-stage investment. The incubator primarily targets groundbreaking European medtech innovations, working closely with physicians and researchers to evaluate over 1,400 ideas, resulting in the creation of 7 companies. With expertise spanning product development, regulatory strategy, and clinical validation, MD Start ensures rapid and capital-efficient progress from idea to market. The team is led by experienced industry veterans like Gérard Hascoët, Anne Osdoit, and Lukas Guenther, who are instrumental in the incubator's success. Their focus is on turning early concepts into disruptive technologies, particularly in therapeutic devices and surgical tools. MD Start’s unique model and strong industry backing make it a vital player in Europe’s medtech landscape.

MDI Ventures is the corporate venture capital arm of Telkom Indonesia, one of Indonesia's largest state-owned telecoms with a market capitalization of approximately $17 billion. Founded in 2016 as an independent entity with its own funding processes, MDI is headquartered in Jakarta with offices in Singapore, the United States, Europe, and South Korea. CEO Donald Wihardja leads the organization. The firm operates multiple sub-funds — including Arise (early-stage) and Centauri (growth-stage, co-managed with KB Financial Group) — and has launched a $200 million fund for early-stage investing. Total AUM reached $290 million by 2019 with a $500 million long-term target. MDI leads rounds and invests across Seed through Series C and beyond, typically writing $1 million to $50 million-plus per deal. Focus sectors include fintech, healthcare, deep tech, agrifood tech, enterprise software, edutech, and consumer, with mid-2025 strategy refocused specifically on AI, cybersecurity, and enterprise software. The portfolio spans 92 companies across 12 countries, producing 6 unicorns (MPL, NIUM, Akulaku, and Loft Orbital, which achieved unicorn status in 2025), 4 IPOs (including WEBUY on NASDAQ in October 2023 at $207 million and RUN System on the IDX), and 11 acquisitions. Co-investors include Sequoia Capital, Google Ventures, Tiger Global, DST, NEA, Bain Capital, Y Combinator, Temasek, and Menlo Ventures. Recent investments include Weiwo, CYFIRMA, Whale (AI), and IDRX (blockchain). MDI's core differentiation is the operational leverage of Telkom Indonesia's nationwide telecommunications infrastructure, enterprise customer base, and government relationships. Portfolio companies gain meaningful commercial acceleration through access to Telkom's distribution network across Southeast Asia's largest digital economy, complemented by co-investment from a global blue-chip investor syndicate.

Medevice Capital is a Paris-based venture capital firm founded in 2011 that specializes in investing in early-stage MedTech and e-health startups. The fund primarily targets innovative companies in the healthcare sector, with a focus on medical devices and diagnostic technologies. Medevice typically invests in rounds ranging from $1 million to $5 million, supporting startups at the seed and later stages​. Some notable portfolio companies include Pixyl, which develops AI-driven medical imaging solutions, and Emagina, focused on women's health with a connected device for perineum care. Medevice also invested in Dyameo, which is working on cancer detection devices​. The firm is led by Cécile Réal, the founder and CEO, and its team has a strong background in healthcare entrepreneurship and investment. Medevice remains active, making approximately two investments per year, particularly within the European market.

Medicxi is a premier European venture capital firm specializing in life sciences, with a focus on drug discovery and therapeutic development. Established in 2016 by the former life sciences team of Index Ventures, the firm has raised over €1 billion across various funds. Medicxi’s flagship funds, such as Medicxi III (€400 million), invest in both early and late-stage biopharma companies. Notable investments include Genmab, Micromet (acquired by Amgen), and Minerva Neurosciences. Medicxi's investment strategy is centered around its "asset-centric" approach, where the firm invests in companies with strong clinical proof-of-concept that address clear unmet medical needs. Their investments typically range between €10 million and €25 million, supporting companies through key phases like clinical development and regulatory approval​. The firm partners closely with major pharmaceutical players such as Novartis, Johnson & Johnson, and GlaxoSmithKline, which provides strategic backing for its portfolio companies​. Headquartered in London, Geneva, and Jersey, Medicxi has become a leading name in European biotech, with a strong emphasis on translating scientific innovation into commercially viable drugs. Their portfolio spans across the full healthcare continuum, from early discovery to late-stage clinical assets, giving them a unique position in Europe’s life sciences ecosystem. Through its deep ties to industry leaders and a robust scientific advisory board, Medicxi continues to drive the next generation of breakthrough therapeutics​.

MedImmune Ventures was the wholly-owned corporate venture capital arm of AstraZeneca, founded in 2002 and headquartered in Gaithersburg, Maryland. The fund managed $400 million in an evergreen structure following AstraZeneca's commitment of an additional $100 million in November 2011. Senior Managing Director Ron Laufer led a team of three partners. Since 2009, the fund operated as a true evergreen vehicle, recycling proceeds from liquidated investments into new portfolio companies rather than returning capital to LPs on a fixed timeline. MedImmune Ventures focused on equity investments in private companies developing small and large molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging, and healthcare IT related to pharmaceutical product discovery and commercialization. Therapeutic areas covered infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system conditions, and gastrointestinal disease. The fund leads rounds. Across approximately 65 investments, the portfolio produced 4 IPOs and 11 acquisitions. Notable holdings include G1 Therapeutics (MedImmune led a $12.5 million Series A in October 2013 and the company later completed a $105 million Nasdaq IPO), Melinta Therapeutics, Astria Therapeutics, and Xencor. The fund also co-led a financing round in NeuProtect Pty Ltd, an Australian cardioprotectant company, alongside Starfish Ventures. MedImmune Ventures is now permanently closed and liquidated. During its active years, the fund served a dual mandate: generating financial returns for AstraZeneca while sourcing strategic intelligence about emerging biotech platforms across areas aligned with the parent company's therapeutic priorities. The evergreen structure allowed for patient capital deployment matched to the long development timelines of biopharmaceutical companies.

Medingenii Capital, based in Houston, Texas, is a venture capital firm specializing in early-stage investments in healthcare, medical devices, healthtech, and life sciences. With a clear focus on disruptive solutions addressing critical challenges in these fields, the firm leverages its deep connections within the Texas Medical Center ecosystem and a global network of co-investors and industry leaders to scale startups for growth and successful exits. Notable portfolio companies include Vitls, Ucardia, and Forest Devices, all of which innovate in life sciences and medical technology. Medingenii’s investment strategy targets healthtech startups, particularly those advancing genomic testing, patient engagement, and medical devices. The firm prefers to engage early, often leading or co-investing in rounds. Their average check size typically hovers around $1.5M. The leadership team, including key figures like Greg Campbell, Diane Yoo, and Eddie Patton, brings decades of entrepreneurial and investment expertise, with a strong emphasis on supporting underrepresented founders and female-led ventures. Medingenii’s unique blend of healthcare specialization and its commitment to diversity position it as a critical player for startups seeking to make a significant impact in the medical and health sectors.

Medison Ventures is the corporate venture capital arm of Medison Pharma, one of the world's largest commercial partners for innovative pharmaceutical companies with operations in Israel, Canada, and Eastern Europe. Founded in 2016 by Meir Jakobsohn and headquartered in Petah Tikva, Israel, the firm focuses on in-licensing, equity investments, and scouting for breakthrough technologies in biotechnology and digital health. Investment activity is concentrated at the Series B stage in life sciences companies. The portfolio comprises approximately 10 investments across biotech, pharma, and digital health. Notable holdings include Alpha Tau Medical, an alpha particle cancer therapy company that completed a NASDAQ IPO in March 2021, along with Keros Therapeutics, Eloxx Pharmaceuticals, Apeiron Biologics, Allogene Therapeutics, Orchard Therapeutics, and ArQule. In 2019, Medison Ventures partnered with Pontifax to launch a $150 million venture debt fund providing clinical-stage life science companies with non-dilutive capital. Portfolio companies benefit from direct access to Medison Pharma's global network of pharmaceutical partners including Biogen, Vertex, Shire, BioMarin, IPSEN, Servier, PTC Therapeutics, and Daiichi-Sankyo. The fund's primary value proposition is commercial access: portfolio companies gain introductions to established pharmaceutical distributors and commercial partners through Medison Pharma's existing relationships, potentially accelerating the path from clinical development to market. The fund is currently presumed inactive with no publicly recorded recent investments, reflecting the typical life cycle of a focused corporate VC vehicle tied to its parent's strategic priorities.

Mediterranean Towers Ventures is an AgeTech-focused corporate venture capital firm backed by Mediterranean Towers (TASE: MDTR), Israel's market-leading retirement living developer and operator. Founded in 2017 and based in Ganei Tikva, Israel, it is the first Israeli investment fund focused exclusively on technological innovations for older adults. The fund opened trading on the Tel Aviv Stock Exchange in a ceremony led by TASE CEO Mr. Ben-Zeev and Mediterranean Towers Chairman Yair Seroussi. Managing Director Omer Brakin, who also serves as VP of Business Development at Mediterranean Towers, leads a team of approximately 12 with backgrounds spanning venture investment, capital markets, real estate, and healthcare. The fund invests at pre-seed and seed stages in Israeli AgeTech startups tackling loneliness, improving medical outcomes, and enhancing quality of life for older adults. Check sizes range from $100,000 to $500,000. The portfolio of six companies includes Maolac (AI-powered bio-functional proteins derived from milk, invested July 2022), Travaxy (accessible travel platform), XRHealth (a VR and AR therapeutic healthcare platform that acquired RealizedCare in February 2025 and NeuroReality in November 2024), Uniper (eldercare fitness), and APA. The fund's primary competitive advantage is direct market access through Mediterranean Towers' retirement communities, providing portfolio companies with four decades of institutional relationships with older adults and real-world testing environments that pure financial investors cannot replicate. Portfolio companies gain structured access to genuine end users, clinical feedback loops, and commercial pathways within the Israeli eldercare ecosystem.

Manifold Ventures (MMV) is a venture capital firm focused on supporting early-stage companies in healthcare innovation. Founded by physicians and healthcare entrepreneurs, MMV invests in startups that are developing groundbreaking medical technologies and solutions. The firm is known for its hands-on approach, offering more than just capital; they provide strategic guidance, operational expertise, and access to an extensive network of industry professionals. Their portfolio includes companies like Stellation (patient-provider matching technology), PocketRN (telehealth nursing), and Gradient Health (a healthcare data marketplace). MMV's team, led by Dr. Branden Rosenhan and Dr. Saumitra Thakur, brings deep experience in both clinical practice and business, which they leverage to help their portfolio companies navigate the complexities of the healthcare industry. MMV is headquartered in Salt Lake City and focuses on identifying promising healthcare innovations early in their development cycle, with the goal of helping these startups scale into successful enterprises.

MedVenture Partners, Inc., a Tokyo-based venture capital firm, specializes in early-stage investments within the life sciences sector, with a distinct focus on medical devices and healthcare technologies. Established in 2013 by Hajime Oshita and Dr. Fumiaki Ikeno, the firm has rapidly built a reputation for identifying and nurturing innovative startups poised to disrupt the healthcare landscape. Their portfolio includes standout companies such as Biomedical Solutions, Inc., which exemplifies their commitment to fostering groundbreaking technologies. MedVenture’s investment strategy is characterized by a hands-on approach, often leading funding rounds and providing substantial guidance to portfolio companies. They prioritize startups that demonstrate strong potential for global impact, particularly those addressing critical medical needs. Their geographic focus remains largely on Japan, but they have shown interest in companies that can expand internationally. With over 22 billion Yen in assets under management, MedVenture manages multiple funds, the most recent of which raised 99 billion Yen. The firm’s approach to investment is strategic and collaborative, leveraging deep medical expertise alongside innovative technology. Startups seeking investment should be prepared to present compelling, well-researched pitches that highlight their innovation and market potential. Led by a team of seasoned professionals, including Oshita, who has over two decades of experience in the medical device industry, MedVenture Partners is committed to driving successful exits and significant market advances. Their active involvement in the growth and development of their portfolio companies underscores their role as a key player in Japan’s venture capital landscape.

MEDX Ventures Group is a Hingham, Massachusetts-based investment and management company founded in 2010 by Harel, who serves as CEO and Company Group Chairman, with offices in the US, Europe, and Israel. The firm focuses on Israeli medical technology and robotic companies, applying a proprietary 'X Model' that provides active management through dedicated Development, Regulatory, Commercial, and Finance teams embedded alongside portfolio companies throughout their lifecycle. In 2015, MEDX raised $30 million for Israeli biomed startups and established MEDX Xelerator, a leading medical-device-focused incubator operating under the auspices of the Israel Innovation Authority. MEDX Xelerator is located in Or Yehuda and Sakhnin, Israel, and partners with Boston Scientific, Sheba Medical Center, Intellectual Ventures, Consensus Business Group, West Pharmaceuticals, Wolfson Hospital, Weill Cornell Medicine Enterprise Innovation, and Ichilov Hospital. Innovation areas include vascular, interventional cardiology, urology, interventional oncology, medical robotics, and digital health solutions. MEDX leads rounds and invests at pre-seed through Series A stages. Across approximately 8 investments, the portfolio includes Microbot Medical (IPO), XACT Robotics (Harel serves as Chairman), Append Medical ($7.4 million Series A), and VeinWay (most recent seed investment, March 2023). The related Edge Medical Ventures launched a $70 million medtech fund to complement MEDX's earlier-stage activity. The MEDX model differs from conventional medtech VCs in that its team actively manages regulatory strategy, commercial development, and financing alongside founders rather than providing capital and periodic board oversight. This hands-on operational approach is designed to reduce time-to-market and de-risk regulatory submissions for hardware-intensive medical devices and robotic surgical systems.

Menlo Ventures, a Silicon Valley-based venture capital firm, has a robust history of investing in transformative technology companies across consumer, enterprise, and healthcare sectors. Notable investments include Uber, Roku, Warby Parker, Poshmark, and Chime. The firm focuses on early-stage investments but supports companies through their entire growth journey. Menlo Ventures recently closed a $1.35 billion fund aimed at backing the next generation of AI startups, reflecting its commitment to cutting-edge technologies. The firm also emphasizes deep involvement with portfolio companies, offering strategic guidance and support through every stage of development.

Merantix is a Berlin-based AI venture studio that has been building and investing in AI-driven startups since 2016. It operates Europe's largest AI platform, focusing on ideating, incubating, and scaling AI ventures across various industries. The company is notable for its emphasis on transformative AI applications, particularly in B2B sectors. Merantix has recently launched a €100 million fund, which is divided into three parts: €25 million for co-investing in external startups, €25 million for incubating new ventures, and €50 million for supporting existing investments. This marks a significant expansion from its traditional model, where it primarily incubated its own startups with an initial €1 million investment in exchange for equity. The firm has incubated successful companies like Vara, an AI breast cancer detection startup, and Cambrium, which focuses on AI-powered protein design. Merantix also hosts the AI Campus in Berlin, a 5,200 sqm co-working and community space dedicated to AI innovation, bringing together startups, corporations, and investors to foster collaboration. Merantix’s investment strategy focuses on early-stage companies, particularly in pre-seed and Series A rounds, with a strong emphasis on supporting founders who have deep domain expertise and a passion for AI.

Mercia Asset Management is a leading UK-based specialist asset manager that focuses on providing capital across four core asset classes: venture capital, private equity, debt, and balance sheet investments. Established initially as a seed capital provider linked to universities, it has grown to manage over £1.4 billion in assets, emphasizing support for small and medium enterprises (SMEs) across the UK, especially in underserved regional markets. The firm’s investment approach is built around its "Complete Connected Capital" model, which combines funds under management (FuM) with direct investments from its balance sheet. This hybrid strategy allows Mercia to offer flexible, long-term capital to startups and scale-ups, typically investing up to £10 million per round. Mercia's extensive portfolio covers sectors such as technology, healthcare, and advanced manufacturing, with notable investments in companies like Oxford Genetics and Netacea. Mercia operates nine regional offices, helping it maintain a close connection with local businesses, and collaborates with government bodies, institutional investors, and private individuals. The firm’s effective management of EIS (Enterprise Investment Scheme) and VCT (Venture Capital Trust) funds has enabled it to deliver consistent returns, achieving an average premium of around 53% on exits. Since its IPO in 2014, Mercia has demonstrated a solid track record in supporting the growth of UK regional businesses while delivering dividends to its investors, underpinning its strategy to be the top regional capital provider in the UK.

Mercia Asset Management, based in the UK, is a leading provider of venture, private equity, and debt financing, with a strong regional focus outside London. With over £1.5 billion in assets under management, Mercia actively backs early-stage businesses in sectors like AI, digital health, clean tech, and biosciences. Notable investments include Netacea (cybersecurity) and Nova Pangaea (sustainable aviation fuel), reflecting its commitment to high-growth sectors. Mercia typically invests between £500k to £20m, supporting startups through multiple stages of growth, including Seed to Series B. The firm’s focus on regional UK businesses helps address funding gaps, with 77% of their recent investments outside London. Their strategy prioritizes long-term partnerships with founders, often maintaining investments for five to seven years. The team, led by CEO Dr. Mark Payton, has a track record of successful exits, including the £100m sale of Faradion and the sale of nDreams to Aonic. Mercia's portfolio also benefits from its affiliation with major initiatives like the Northern Powerhouse Investment Fund, which helps accelerate regional growth. Mercia is known for being approachable and hands-on, offering mentorship alongside capital​.

Mercury Fund is an early-stage venture capital firm based in the U.S. that focuses on software startups, primarily in Middle America. Founded with the mission of driving innovation outside of coastal tech hubs, Mercury has built a portfolio that spans sectors such as SaaS, AI, and fintech. The firm has helped create over $9 billion in value by supporting transformative businesses, particularly in areas like enterprise SaaS, industrial IoT, and tech-enabled services. Mercury typically invests between $1 million and $4 million in Seed and Series A rounds, while also providing follow-on funding of up to $8 million over the life of a company. They act as lead or co-lead investors, helping startups achieve sustainable growth through their proprietary operational framework, which focuses on improving business processes early in a company's development. Notable companies in their portfolio include Cart.com, Benson Hill, and Amify. The firm takes pride in backing both first-time founders and seasoned entrepreneurs, offering them access to a vast network of growth partners and resources.

Meridian Street Capital is a venture capital firm established in 2016, based in New York City. The firm specializes in early-stage investments at the intersection of healthcare and technology. Their approach is to support founders from the earliest stages, often from day one, to help turn innovative ideas into category-defining companies. Meridian Street Capital has a strong portfolio that includes companies like 1upHealth, ClosedLoop.ai, and Jona Health, among others. They focus on investing in businesses that leverage technology to improve healthcare services, access, and efficiency. Typically, their investments range from $100K to $5M, with a sweet spot around $1.5M. The firm has a hands-on approach, providing strategic guidance and leveraging their industry connections to support the growth of their portfolio companies. The team at Meridian Street Capital includes key figures such as George Ribaroff and T. Scott Law Jr., who bring extensive experience in venture capital and healthcare technology. They have a focused strategy, partnering with a concentrated group of startups to ensure dedicated support and resources. Meridian Street Capital has made a total of 47 investments and has seen several successful exits, including Valify and Hint Health. Their investment strategy emphasizes backing exceptional teams with innovative solutions that have the potential to transform healthcare.

Meritech Capital Partners is a leading late-stage venture capital firm based in Palo Alto, California, established in 1999. The firm specializes in investing in high-growth technology companies, typically engaging during Series B and Series C rounds. With a focus on sectors such as data analytics, software, fintech, and consumer internet, Meritech has played a significant role in scaling industry-leading businesses. Notable investments include high-profile names like Salesforce, Facebook, Datadog, Roblox, and Snowflake. Meritech’s strategy revolves around selective, disciplined investing, ensuring they work closely with each company to help drive operational excellence and strategic growth. The firm's latest Fund VII closed with $800 million, reinforcing its commitment to backing transformative technologies across cloud computing, AI, and enterprise software. They take a hands-on approach, where partners actively collaborate with founders to refine go-to-market strategies and expand business reach. What sets Meritech apart is their streamlined structure, emphasizing long-term partnerships rather than a wide, fragmented investment spread. This allows them to be deeply involved with their portfolio companies, providing not just capital but also strategic guidance, leveraging decades of expertise in tech investing. Headquartered in Silicon Valley, Meritech continues to be a key player in empowering the next generation of technology leaders by supporting growth-stage companies with potential for market disruption and leadership.

Meron Capital, founded in 2017 and based in Tel Aviv, is an early-stage venture capital firm focused on investing in deep-technology software startups. The firm, led by managing partners Liron Azrielant and Daniel Roditi, has raised two funds, Meron I and Meron II, each with $50 million. Meron Capital primarily invests in sectors such as enterprise software, cybersecurity, digital health, fintech, and DevOps, targeting pre-seed and seed-stage companies. Notable investments by Meron Capital include Loom Systems, acquired by ServiceNow; Reshuffle, acquired by Twitter; Clear Genetics, acquired by Invitae; and Axonize, acquired by Planon. The firm’s current portfolio also includes promising startups like LendAI, Sorbet, Firmbase, and Laminar​. Meron Capital prides itself on a founder-first approach, providing not just capital but also strategic guidance and leveraging their extensive network to help startups scale. They emphasize backing resilient and technically proficient founders who are capable of pushing through challenges and leveraging subtle expert feedback to refine their business models​.

Merus Capital, founded in 2008 and based in Palo Alto, California, focuses on early-stage investments, primarily from pre-seed to Series A rounds. The firm specializes in sectors such as HR tech, big data and analytics, artificial intelligence and machine learning, biotech, and developer tools. Merus Capital has made 104 investments and has had 30 successful exits, including notable companies like Amplitude, Iterable, and Symphony​. Other prominent portfolio companies include Emi Labs, Censia, Moesif, and Modern Health​. Co-founded by Sean Dempsey, Salman Ullah, and Peter Hsing, Merus Capital aims to support ambitious teams that are building industry-defining platforms. The firm offers substantial follow-on capital and leverages its extensive network to help portfolio companies scale effectively​.

Metaplanet Holdings, founded in 2011 by Jaan Tallinn, co-founder of Skype, is a venture capital firm based in Tallinn, Estonia. The firm focuses on early-stage investments in deep technology startups that promise long-term societal and civilizational impacts. Metaplanet emphasizes funding science-heavy projects and non-commercial research aimed at reducing existential risks, particularly from AI and other advanced technologies. Metaplanet has a diversified portfolio of over 150 startups, with notable investments including BillionToOne, a provider of cell-free cancer liquid biopsy tests, and Anthropic, an AI-based conversational chatbot service. The firm has made more than 50 successful exits, including companies like Ampler Bikes and Apprente. Recent investments include $7 million in the blockchain company Fhenix and $13 million in Neurable, a brain-computer interface technology company. The firm's investment strategy focuses on sectors such as AI, neuroscience, blockchain, and encryption, supporting innovations that have the potential to disrupt industries or create entirely new ones. Metaplanet's team, led by Managing Partner Rauno Miljand and Partner Alexey Morgunov, operates with a lean structure, enabling them to make impactful and strategic investments.

MetaProp is the leading venture capital firm specializing in PropTech, blending physical and digital real estate innovations. Established in 2015 and headquartered in New York City, MetaProp has invested in over 150 PropTech startups, such as Attentive, Spruce, and Bowery, creating significant enterprise value across a 20 billion square foot real estate portfolio. MetaProp's primary investment focus is on early-stage PropTech companies that offer software, IoT, and tech-enabled services. The firm’s geographic reach is global, with notable partners across North America, Asia, and Europe. MetaProp’s investment strategy emphasizes hands-on support, providing startups with mentorship, strategic advice, and industry connections. The firm’s average investment ranges between $150,000 to $2 million, and they are known for leading investment rounds. Key team members include co-founders Aaron Block and Zak Schwarzman, who bring a wealth of experience and deep industry connections. The team is complemented by executives like Maureen Waters and Monica O’Neill, who bolster MetaProp’s commitment to supporting their portfolio companies. To engage with MetaProp, startups are encouraged to leverage their extensive network and proactive approach by pitching through their formal channels or connecting at industry events. MetaProp's accelerator program at Columbia University and other global initiatives further highlight their dedication to fostering innovation in the real estate sector.

Metavallon VC, founded in 2018 and based in Athens, Greece, focuses on early-stage investments in technology startups, particularly those connected to Greece. They typically invest in seed and pre-seed stages, with initial funding tickets ranging from €500K to €1.5M. The firm emphasizes supporting startups in sectors like transportation and mobility, energy and cleantech, space and aviation, machine learning and AI, and more. Notable investments by Metavallon VC include Ferryhopper, a leading ferry booking platform, and Wikifarmer, which aims to democratize agricultural commerce. The firm has also successfully exited from companies such as Seervision, which specializes in AI-driven camera automation software, and Think Silicon, a provider of graphics technology solutions. Metavallon VC offers extensive support to their portfolio companies, including business development, B2B sales, recruiting, and exit planning. Their approach combines financial backing with hands-on guidance to help startups scale and achieve significant market impact. The leadership team includes George Karantonis, Myrto Papathanou, and Yorgos Mousmoulas, who bring extensive experience in venture capital and technology investments.

Metrodora Ventures is a New York-based venture capital firm founded in 2020 by Chelsea Clinton. The firm focuses on early-stage investments in the health and learning sectors, with a mission to support companies that improve access to care, education, and vital information. Metrodora Ventures is driven by a values-conscious approach, investing in purpose-driven startups that aim to make a significant impact on society. The firm’s portfolio includes innovative companies like Teal Health, which is developing telehealth platforms focused on women’s health, and Blooming Health, which creates technology to help older adults maintain connections with their communities. Another notable investment is Swing Therapeutics, which develops digital therapies for chronic illness management. Metrodora Ventures operates with the goal of nurturing its portfolio companies by providing capital, market insights, and industry relationships. The firm raised its debut fund of $20.8 million and is currently in the process of raising a second fund to continue its mission of fostering impactful startups.

Founded in 2018, Metropolis VC is a global venture capital firm headquartered in Beijing, China, with a strong focus on early-stage investments in technology and digital-first businesses. Leveraging a team experienced in major tech companies such as Google and Nokia/Microsoft, Metropolis brings strategic depth to its partnerships. The firm is active in identifying promising startups that aim to disrupt traditional markets through innovation and cutting-edge technology. Key investments include Inbox Health, a leader in health tech, Prevu, a real estate technology platform, and TraceAir, which uses AI for construction management. Metropolis VC operates with a collaborative approach, often participating in seed and Series A rounds, providing customized funding amounts that align with a startup's specific needs. The firm’s investment strategy focuses on fostering long-term partnerships, not just providing capital but supporting product development and go-to-market strategies. This approach is led by Andrew Zubrilin, a prominent partner based in New York, who guides their investment philosophy and strategic engagements. With an active portfolio spanning various sectors, Metropolis has established itself as a dynamic player in the venture capital ecosystem. Although its core operations are anchored in the U.S. and China, the firm holds a global perspective, ready to invest in transformative tech across borders. This mix of geographic diversity and deep technological expertise enables Metropolis to be a key supporter of innovative startups aiming for accelerated growth and market leadership.

Noshaq is an investment fund based in Liège, Belgium, that offers a range of financing solutions aimed at fostering the creation and growth of companies, particularly SMEs. Established in 1985 under the name Meusinvest, the organization has grown significantly and rebranded to Noshaq in 2019 to better reflect its innovative and dynamic approach to investment. Noshaq manages a portfolio of 477 companies and has supported over 1,020 companies since its inception. The fund's primary focus areas include biotechnology, industry 4.0, digital technology, quality food, real estate, energy, sustainable development, and cultural industries. They provide funding through various vehicles, including equity investments, loans, and leasing, tailored to the specific needs of each stage of a company's development. Notable initiatives under Noshaq include Noshaq Spin-Offs, which supports the creation of spin-offs in collaboration with the University of Liège, and LeanSquare, which focuses on innovative projects in cultural and creative industries, enterprise software, and life sciences. Additionally, Noshaq is actively involved in regional development projects, such as La Grand Poste, a creative hub in the heart of Liège.

Meyer Ventures LLC is a New York City-based early-stage venture capital firm and the investment arm of Ocean Road Advisors, Inc., a family office managing more than $750 million in assets. The family office was founded in 2005 to oversee the assets of Edward H. Meyer, the former longstanding Chairman, President, and CEO of Grey Global Group, one of the world's largest advertising and media companies. Anthony E. Meyer serves as CEO of Meyer Ventures, President of Ocean Road Advisors, and Chairman of Meyer and Co. LLC, a merchant banking firm. The firm incubates and sponsors new ventures, invests in early-stage companies, and provides growth capital, strategic management, and financial advisory services, typically writing checks between $500,000 and $3 million at Seed and Series A stages and leading rounds. Focus areas include marketing and media, healthcare, education, and financial services. Across 26 investments with 7 recorded exits, the portfolio includes Volastra Therapeutics (Series A, March 2023 — most recent investment), Graduation Alliance (formerly The American Academy, an online education and corporate training company founded by Anthony Meyer in 2007 and sold to a PE impact fund in early 2020), and Critical Mention (most recent exit, May 2022). Meyer Ventures draws on the family's deep operating heritage in advertising and media — Grey Global Group's legacy — to identify and support founders building companies at the intersection of marketing, health, and education technology. The family office structure enables patient capital deployment without the return-driven timeline pressures of a conventional institutional fund.

MFV Partners (legally Mobile Foundation Ventures) is an early-stage deep-tech venture capital firm founded in 2018 and based in Los Altos, California. The firm was established by Founding Managing Partner Karthee Madasamy, who spent eleven years as a corporate VP and Managing Director at Qualcomm Ventures before launching MFV. The investment team also includes Chairman and Partner Ashish Gupta and Partner Dr. Ruchi Dana. MFV invests exclusively in deep tech transforming physical industries, concentrating on core AI, robotics, sensors, computer vision, smart manufacturing, ag-tech, quantum computing, IoT, and energy transition. The firm explicitly avoids fintech, digital media, and marketplaces. Typical stages are seed and Series A, with check sizes between $500,000 and $3 million and a sweet-spot of approximately $1.5 million. MFV leads rounds. Over its first seven years the firm has made approximately 14 investments, including PsiQuantum (optical quantum computing, $1 billion round at a $7 billion valuation backed by NVIDIA), Agility Robotics (humanoid robotics), Chef Robotics (food-assembly systems that have packaged more than 30 million meals), SUN Mobility (battery-swap infrastructure with more than 20 million swaps across 1,000+ stations globally), Rescale (high-performance computing), and Ati Motors ($20 million Series B). In February 2025 MFV led a round in OpenInfer, an edge AI compute company. In May 2025 MFV also launched Harper Court Ventures Fund I, a $25 million pre-seed and seed vehicle in exclusive partnership with the University of Chicago to commercialize quantum, AI, energy, and life-sciences research. MFV's approach is deliberately narrow and thesis-driven, backing companies that solve hard engineering problems with durable competitive moats. The team's deep roots in semiconductor and wireless technology give portfolio companies credibility and access when engaging with large industrial and enterprise customers.

MHS Capital, founded in 2006 and based in San Francisco, California, focuses on early-stage investments in technology-driven companies. They have a diverse portfolio, investing across sectors such as software, e-commerce, mobile, and healthcare. Notable investments include companies like Zenput, a business productivity software, and Grove Collaborative, an eco-friendly consumer goods company. MHS Capital has made a total of 102 investments, with 48 successful exits, including companies like Udemy and Thumbtack. The firm emphasizes close collaboration with visionary founders to build the next generation of category-defining companies.

mHUB, based in Chicago, is a leading innovation center for hardtech and manufacturing startups. Founded in 2017, mHUB has quickly established itself as a key player in driving innovation across various sectors, including climate tech, medtech, and smart manufacturing. Through its Product Impact Fund I, mHUB has invested in 46 startups, with a significant focus on sustainable manufacturing and clean energy technologies. Notable investments include Sensatek Propulsion Technology, Aeternal Upcycling, and Next-Ion, among others. mHUB’s strategic approach combines capital investment with robust support through its accelerator programs, providing startups with access to extensive prototyping labs, a vast network of industry mentors, and business leadership training. The mHUB community has generated over $1.89 billion in revenue, launched more than 1,600 products, and created over 5,500 jobs since its inception. The organization’s commitment to diversity is evident, with investments in underrepresented founders being 6.5 times higher than the national average. Key team members like Haven Allen, CEO and co-founder, and Melissa Lederer, Chief Experience Officer, play pivotal roles in steering the fund and supporting its portfolio companies towards commercialization and market success. Situated at the intersection of Chicago’s tech and manufacturing districts, mHUB leverages its location within an Opportunity Zone and Planned Manufacturing District to offer unique benefits to startups, such as eligibility for specific funding opportunities and federal contracts. With its new 80,000 square foot facility, mHUB continues to expand its capacity to support innovation and drive economic growth in the region.

Miami Angels, founded in 2013, is one of Florida's largest and most active angel networks. The group focuses on post-product, post-revenue, early-stage technology companies, and is industry agnostic. Their portfolio includes over 60 companies with more than $32 million invested. The organization works through its individual members, who make investments rather than the network itself. This allows for a diverse range of opportunities and perspectives within the tech startup ecosystem. Miami Angels supports various startups, including Caribu, Nearpod, and ClassTag, which span industries from educational technology to enterprise solutions​. Miami Angels values partnerships and collaborations, which help provide exceptional services and support to the companies in their network. Key partners include Kaufman Rossin, a leading accounting and advisory firm.

Mica Ventures is a corporate venture capital firm based in Sugar Land, Texas. The firm focuses on strategic investments in startups that align with its business interests, particularly in consumer technology. Founded by William Penczak, Mica Ventures emphasizes a metrics-based approach to business planning, helping companies enhance revenue and improve margins. The firm combines strategic insights with tactical execution, aiming to bridge the gap between high-level strategies and actionable market plans, often referred to as having a "bias towards action." Although Mica Ventures has a relatively low activity level, it has been involved in key investments such as its participation in a $13.5 million funding round for Supersapiens, a health tech company based in Atlanta that focuses on glucose monitoring for athletes. This indicates Mica's interest in the health and wellness sector, alongside broader consumer tech categories. The firm’s philosophy centers on helping companies grow sustainably by leveraging data-driven marketing and sales strategies. This includes initiatives ranging from market research and digital marketing to more specific efforts like sales compensation programs and pipeline development. Mica Ventures stands out for its focus on sustainable business growth, and its strategic guidance is designed to help startups achieve long-term success through practical and efficient market execution.

The University of Michigan's Innovation Partnerships manages several initiatives to support startups emerging from university research, focusing on areas like life sciences, technology, and advanced manufacturing. A key part of this ecosystem is the Michigan Biomedical Venture Fund (MBVF), which invests in early-stage companies developing therapeutics, diagnostics, medical devices, and health IT solutions based on U-M licensed intellectual property. Collaborating with the College of Engineering and the Fast Forward Medical Innovation (FFMI) program, MBVF aims to drive commercialization and enhance Michigan's role in healthcare innovation. In addition, the Michigan University Innovation Capital Fund (MUICF) provides pre-seed funding to startups originating from across Michigan’s public universities. With $5 million under management, the fund is designed to help companies navigate their early stages by providing capital, strategic guidance, and networking opportunities. The fund is part of a broader consortium that unites tech transfer offices from institutions like Michigan State, Wayne State, and Western Michigan, aiming to accelerate the commercialization of university research and foster statewide economic growth. Overall, the University of Michigan's ventures are structured to bridge the gap between academia and industry, ensuring that innovative research translates into impactful, commercially viable solutions. These efforts are backed by funding from the Michigan Economic Development Corporation, reinforcing the university's commitment to driving innovation and supporting the local economy.

Micron Ventures, the venture capital arm of Micron Technology, focuses on early-stage investments in deep tech startups, particularly those working on AI, machine learning, and innovative hardware solutions. With two dedicated funds—totaling $300 million—the firm aims to accelerate innovations that can transform compute infrastructure and AI-driven applications. Fund II, launched with $200 million, emphasizes deep tech innovations and earmarks 20% of its capital for startups led by women and underrepresented groups. Micron Ventures has a track record of backing high-potential companies, contributing not only capital but also strategic support to help them scale globally. Some notable investments include Aqua Membranes, a clean-tech company focused on sustainable water solutions, and Iterative Scopes, a company leveraging AI to advance healthcare diagnostics. The firm’s portfolio also spans sectors like autonomous systems and cybersecurity, with key investments in SambaNova and Mythic AI. Micron Ventures integrates its investment strategy with its corporate goals, especially in sustainability and AI. By investing in companies at the intersection of hardware and software innovation, Micron Ventures helps push technological boundaries while also advancing Micron’s business objectives.

Middle East Venture Partners (MEVP) is one of the largest and most established venture capital firms in the Middle East, with a focus on investing in early and growth-stage technology startups across the GCC and Levant regions. Founded in 2010, MEVP manages over $300 million in assets and has invested in more than 60 startups, many of which operate in sectors such as fintech, e-commerce, mobility, SaaS, and healthtech. With offices in Dubai, Beirut, Bahrain, and Riyadh, MEVP targets innovative companies that have the potential to scale regionally and globally. Their portfolio includes successful companies like Anghami, the first legal music streaming platform in the Arab world to go public, Nana, a leading online grocery delivery service, and Bykea, a Pakistani super app offering transport and delivery services. MEVP offers both financial backing and strategic support to help these businesses grow, focusing on building sustainable, scalable models that align with local market needs. MEVP has also made significant exits, such as its partial exit from Fresha, a beauty and wellness platform, generating impressive returns. With its recent launch of the $150 million Middle East Venture Fund IV, MEVP continues to drive innovation by supporting digital services and tech-based solutions that address local challenges and tap into global trends​.

Middleland Capital, a venture capital firm founded in 2010 and based in Washington, D.C., focuses on innovative foodtech and agtech companies. With over $100 million invested and a portfolio of 25 direct investments, the firm supports high-growth companies that are looking to scale their de-risked technology and proven business models​. The firm's notable investments include AeroFarms, the largest indoor vertical farming company in the US; Soli Organic, a leading grower and marketer of fresh organic culinary herbs; and MycoTechnology, an ingredient company that utilizes proprietary processes to remove flavor defects in food products without chemicals or GMOs​​. Other significant investments include EarthOptics, which provides real-time soil data maps, and Farmwise, which develops systems to streamline farming operations and increase food production efficiency​. Middleland Capital has a strong track record of successful exits, such as Seventh Generation, which was acquired by Unilever, and Benson Hill, which went public on the NYSE. The firm continues to catalyze global change in food and health through its targeted investments in innovative technologies and sustainable solutions.

Midven, now part of Future Planet Capital, is a prominent venture capital firm based in Birmingham, UK. With over 30 years of experience, Midven focuses on early-stage and growth-stage companies, providing essential capital to support high-growth potential businesses. The firm is actively involved in the Midlands region, offering funding through various initiatives like the Midlands Engine Investment Fund (MEIF) and the West Midlands Co-Investment Fund​​. Midven has a strong track record, supporting innovative companies across diverse sectors such as technology, healthcare, and advanced manufacturing. Notable portfolio companies include Cipher Surgical, Connexica, and CrowdControlHQ, showcasing their commitment to fostering groundbreaking enterprises​​. Following its acquisition by Future Planet Capital, Midven has enhanced its global reach and resources, linking its regional investments with international scientific research and innovation networks. This merger aims to leverage global expertise and capital to scale up UK-based scientific and technological advancements​​. For startups seeking investment, Midven looks for businesses with a clear vision, strong management teams, and significant growth potential. The firm provides not just funding but also strategic support to help companies achieve their growth objectives and drive economic impact in the region​.